# Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children

> **NCT02899702** · PHASE4 · WITHDRAWN · sponsor: **Hospices Civils de Lyon**

## Conditions studied

- Staphylococcal Infection
- Streptococcal Infection

## Interventions

- **DRUG:** PRIVIGEN (CSL Behring)
- **DRUG:** Albumin

## Key facts

- **NCT ID:** NCT02899702
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-09
- **Primary completion:** 2024-09
- **Final completion:** 2024-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** no EC approval obtained
- **Last updated:** 2021-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02899702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02899702, "Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02899702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*